How many papers support this gap analysis?

3 papers from our local library contribute to this synthesis, with an average publication year of 2024.

Can I get a manuscript addressing this gap reviewed here?

Yes — AI Review runs 8 specialised agents over the full PDF and returns a structured editorial report in one pass, for 30 credits. Start at /review. An open-access publication route is in preparation and is not open for submissions yet.

medicine3 papersavg year 2024weak evidence

IGF1R is not established as a validated therapeutic

Research gap analysis derived from 3 medicine papers in our local library.

The gap

IGF1R is not established as a validated therapeutic target in endometrial cancer molecular classification or clinical trials. Current endometrial cancer treatment guidelines emphasize MMR status, EGFR, HER2, and immunotherapy, but no clinic

Evidence profile

Stated in the synthesized section of the source papers, classified as general, drawn from work published between 2023 and 2024, spanning 3 journals. Those papers have been cited 186 times in total.

Research trend

Established — well-defined area with open sub-problems.

Supporting evidence — 4 representative gaps

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives (2024) · International Journal of Molecular Sciences · cited 93× · doi
No in silico comparative binding study of low-cost generic compounds against IGF1R kinase domain has been conducted for endometrial cancer. While computational technologies are recognized as vital for accelerating kinase inhibitor development and drug repurposing, existing work focuses on approved kinase inhibitors and established targets like EGFR and HER2, leaving IGF1R-targeted repurposing unexplored in this cancer type.
generalstated in synthesizedevidence 5/5
Keywords: silico comparative binding study low-cost generic compounds against
Adjuvant treatment of endometrial cancers: systematic review and perspectives (2024) · Journal of Cancer Prevention & Current Research · doi
IGF1R is not established as a validated therapeutic target in endometrial cancer molecular classification or clinical trials. Current endometrial cancer treatment guidelines emphasize MMR status, EGFR, HER2, and immunotherapy, but no clinical evidence or molecular profiling data links IGF1R overexpression to endometrial cancer prognosis or treatment response.
generalstated in synthesizedevidence 5/5
Keywords: igf1r established validated therapeutic target endometrial cancer molecular
COMPARATIVE ANALYSIS OF THE USE OF MAINTENANCE THERAPY DRUGS IN WOMEN IN THE PROCESS OF RADIOTHERAPY AFTER SURGICAL TREATMENT OF ENDOMETRIAL CANCER (2023) · Vrach · doi
No pharmacoeconomic comparison exists between generic IGF1R inhibitors and current standard-of-care endometrial cancer therapeutics (lenvatinib, pembrolizumab, chemotherapy). While cost-effectiveness analysis is performed for maintenance drugs in endometrial cancer, no study evaluates the cost-benefit of repurposed generic kinase inhibitors against established first-line or second-line regimens.
generalstated in synthesizedevidence 5/5
Keywords: pharmacoeconomic comparison exists between generic igf1r inhibitors current
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives (2024) · International Journal of Molecular Sciences · cited 93× · doi
Binding affinity and selectivity of generic compounds against IGF1R kinase domain (PDB 1K3A) relative to off-target kinases (EGFR, HER2, etc.) have not been computationally characterized. Existing kinase inhibitor development emphasizes overcoming drug resistance and toxicity from off-target effects, but no docking or molecular dynamics study addresses IGF1R selectivity for generic repurposed agents.
generalstated in synthesizedevidence 5/5
Keywords: binding affinity selectivity generic compounds against igf1r kinase

Questions about this gap

IGF1R is not established as a validated therapeutic target in endometrial cancer molecular classification or clinical trials. Current endometrial cancer treatment guidelines emphas… This is supported by 4 representative gap statements extracted from 3 papers, rated weak evidence.

Explore this gap further

Run this gap as a query across open scholarly engines for the latest related literature.

Find research gaps on this topic →Google Scholar ↗Semantic Scholar ↗OpenAlex ↗Europe PMC ↗CORE ↗

Working on this gap? Review it with us.

Science AI Journal reviews manuscripts in one pass with 8 specialised AI agents calibrated on 69,000+ real peer reviews.

Run an AI review Run a pre-submission check

Tools for your next paper

Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.AI Review8 specialist agents return an editor-ready review of your full PDF.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.